The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I don't think we will ever make any money investing in JIM? It seems to be run solely by and for the purpose of Mr Gr#@t and his family. If JIM is still being advised how to run their operation, within the rules of the FCA, and have lost model B firms because of apparent poor controls then Mr Gr#@t is the one responsible for all this?
You are better off investing elsewhere IMHO.
DYOR
Hi RoxburyHouse,
I'm hoping the same....otherwise, why would anyone transfer shares which are currently "worthless"?
Furthermore, this transaction cannot be a member of the public and has to be by someone in the know? In which case there should be a formal RNS notifying the public what this is in relation to?
OF has not put any news of this 4D Pharma "issue" on their website - now 4 days after the event!
OF were quick to announce that they had loaned $30m to 4D on 29/07/21!
Can anyone confirm if this is still happening and, if so, is anyone attending please?
Surely, a formal RNS has to be made one way or the other?
Thanks.
Published: June 24, 2022 at 6:59 a.m. ET
Merck & Co. on Friday said the European Commission approved the expanded use of its blockbuster cancer drug Keytruda for certain patients with melanoma, the most serious form of skin cancer.
The Kenilworth, N.J., drugmaker said Keytruda is now approved as monotherapy for the treatment of people ages 12 and older with stage IIB or IIC melanoma and who have undergone complete resection.
Merck said the commission also approved expanding the indications for Keytruda in advanced melanoma and stage III melanoma, as adjuvant treatment following complete resection, to include adolescent patients ages 12 and up.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world. Sales of the drug topped $17 billion last year.
Well done Adamski1.
This is probably what the majority of long term investors are wanting to know so thanks for emailing DDDD.
If anyone from their Investor Relations team (or even senior management) perhaps they will realise our frustrations.
May be the Board or senior management team are not able to buy any further shares at present due to whatever is happening in the background...who knows?
It will be interesting to see how they respond (if they do).
In the meantime, I'm holding on as I really believe that good days are not too far away.
Best wishes everyone.
"this time next year, we will all be_____________"
As we wrap up 2021, we’re encouraged by the increased understanding of the influence of the #microbiome on nearly all systems in the human body, not just the gut. Throughout 2021, more clinical data from @4Dpharmaplc and others in the field, in an ever more diverse set of diseases, further established the role of the microbiome in the future of healthcare. This in turn has driven yet more collaborations and investment in the space.
In 2022, we look forward to the continued advancement of our pipeline of #LiveBiotherapeutics for diseases ranging from #cancer to #asthma to #Parkinsons. Learn more here: https://lnkd.in/d-syMV77
The global asthma treatment market size stood at USD 18.08 billion in 2019 and is projected to reach USD 26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period....
Just saying.
GLA
Funny how the price seems to rise each time the yanks have a bank holiday!
No doubt the price will fall back tomorrow when the Yankee whiz kids resume playing with their bots!
If you were on the Board/Management Team of Amazon, would you be looking at making a bid for ASOS? Surely, now is the perfect time to pounce? ASOS needs a new leader and new direction. AMAZON Market Cap is $1.67T with ASOS's Market Cap at £2.4B?
I notice on the 4D website that CHARDAN (Global Investment Bank) has recently been added to their Analyst Coverage page.
The more the merrier hey?
There are currently no open short positions in 4d Pharma Plc. - 02/08/2021.
Is it just me or would anyone else love to know who is behind all this "bot trading" on DDDD (which seems to happen at the open, lunchtime and the close of business)? When I say "trading" I don't believe any real trades of size are going through at these prices?
In comparison with other shares on my watch list, the bid/offer prices of DDDD seem to change more frequently?
Any ideas please?
Please note the date of 1st July 2021. Will there be an update prior to or on this date his????
AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces Christophe Carite, Development Director, will deliver a presentation on 4D pharma's strategy and capabilities for the manufacturing of its Live Biotherapeutic drug candidates at the upcoming virtual Microbiome Movement Drug Development Summit, on Thursday, July 1 at 2.15pm EDT (7.15pm BST). He will also participate in a microbiome therapeutics manufacturing roundtable panel session.
T
May be a big buyer who set a limit around the 98p mark ahead of the next Presentation on 1st July 2021?
MM's working the order and tree shaking ?
https://twitter.com/AntMwah/status/1407622576747302914/photo/1
Thanks for spotting Amphiprion1